Edwards Lifesciences Corp (EW)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net sales | 1,532.2 | 1,412.7 | 1,354.4 | 1,385.9 |
| Cost of sales | 344.4 | 301.6 | 262.9 | 285.3 |
| Gross profit | 1,187.8 | 1,111.1 | 1,091.5 | 1,100.6 |
| Certain litigation expenses | 15.5 | 10.9 | 10.8 | 8.1 |
| Other operating income | 21.3 | 19.1 | -22.4 | - |
| Research and development expenses | 276.2 | 254.6 | 253.4 | 272.6 |
| Separation costs (note 3) | 4.2 | 4.2 | - | - |
| Selling, general, and administrative expenses | 502 | 465.7 | 421.4 | 450.8 |
| Change in fair value of contingent consideration liabilities (note 9) | - | - | - | - |
| Restructuring expenses (note4) | - | - | 32.9 | - |
| Operating income, net | 411.2 | 394.8 | 350.6 | 369.1 |
| Interest income, net | 37.4 | 36.5 | - | - |
| Loss on impairment | 47.1 | - | - | - |
| Other non-operating expense (income), net | -1.3 | 2.6 | 27.9 | 2 |
| Interest income, net | - | - | 24.3 | 15.5 |
| Income from continuing operations before provision for income taxes | 400.2 | 433.9 | 402.8 | 386.6 |
| Provision for income taxes | 64.3 | 70.3 | 40.7 | 20.2 |
| Net income from continuing operations | 335.9 | 363.6 | 362.1 | 366.4 |
| (loss) income from discontinued operations, net of tax | -4.4 | -7.2 | 2,707.3 | -1.4 |
| Net income | 331.5 | 356.4 | 3,069.4 | 365 |
| Net loss attributable to noncontrolling interest | -1.7 | -1.6 | -1.4 | -1.3 |
| Net income attributable to edwards lifesciences corporation | 333.2 | 358 | 3,070.8 | 366.3 |
| Basic (in shares) | 587,000,000 | 586,900,000 | 597,200,000 | 602,100,000 |
| Basic earnings per share (in dollars per share) | 0.57 | 0.61 | 5.14 | 0.61 |
| Diluted (in shares) | 587,900,000 | 587,800,000 | 598,100,000 | 604,300,000 |
| Diluted earnings per share (in dollars per share) | 0.56 | 0.61 | 5.13 | 0.61 |